600 related articles for article (PubMed ID: 10789606)
1. Effect of antiretroviral therapy on viral load, CD4 cell count, and progression to acquired immunodeficiency syndrome in a community human immunodeficiency virus-infected cohort. Swiss HIV Cohort Study.
Erb P; Battegay M; Zimmerli W; Rickenbach M; Egger M
Arch Intern Med; 2000 Apr; 160(8):1134-40. PubMed ID: 10789606
[TBL] [Abstract][Full Text] [Related]
2. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
[TBL] [Abstract][Full Text] [Related]
3. Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. Royal Free Centre for HIV Medicine.
Mocroft A; Devereux H; Kinloch-de-Loes S; Wilson D; Madge S; Youle M; Tyrer M; Loveday C; Phillips AN; Johnson MA
AIDS; 2000 Jul; 14(11):1545-52. PubMed ID: 10983641
[TBL] [Abstract][Full Text] [Related]
4. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
[TBL] [Abstract][Full Text] [Related]
5. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
[TBL] [Abstract][Full Text] [Related]
6. Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1.
Emu B; Fessel J; Schrader S; Kumar P; Richmond G; Win S; Weinheimer S; Marsolais C; Lewis S
N Engl J Med; 2018 Aug; 379(7):645-654. PubMed ID: 30110589
[TBL] [Abstract][Full Text] [Related]
7. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
Bonnet F; Thiébaut R; Chêne G; Neau D; Pellegrin JL; Mercié P; Beylot J; Dabis F; Salamon R; Morlat P;
HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy.
Hermankova M; Ray SC; Ruff C; Powell-Davis M; Ingersoll R; D'Aquila RT; Quinn TC; Siliciano JD; Siliciano RF; Persaud D
JAMA; 2001 Jul; 286(2):196-207. PubMed ID: 11448283
[TBL] [Abstract][Full Text] [Related]
9. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study.
Ledergerber B; Egger M; Opravil M; Telenti A; Hirschel B; Battegay M; Vernazza P; Sudre P; Flepp M; Furrer H; Francioli P; Weber R
Lancet; 1999 Mar; 353(9156):863-8. PubMed ID: 10093977
[TBL] [Abstract][Full Text] [Related]
10. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men.
Sterling TR; Vlahov D; Astemborski J; Hoover DR; Margolick JB; Quinn TC
N Engl J Med; 2001 Mar; 344(10):720-5. PubMed ID: 11236775
[TBL] [Abstract][Full Text] [Related]
11. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies.
Chêne G; Sterne JA; May M; Costagliola D; Ledergerber B; Phillips AN; Dabis F; Lundgren J; D'Arminio Monforte A; de Wolf F; Hogg R; Reiss P; Justice A; Leport C; Staszewski S; Gill J; Fatkenheuer G; Egger ME;
Lancet; 2003 Aug; 362(9385):679-86. PubMed ID: 12957089
[TBL] [Abstract][Full Text] [Related]
12. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study.
Paredes R; Mocroft A; Kirk O; Lazzarin A; Barton SE; van Lunzen J; Katzenstein TL; Antunes F; Lundgren JD; Clotet B
Arch Intern Med; 2000 Apr; 160(8):1123-32. PubMed ID: 10789605
[TBL] [Abstract][Full Text] [Related]
13. Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients. Swiss HIV Cohort Study.
Khanna N; Klimkait T; Schiffer V; Irigoyen J; Telenti A; Hirschel B; Battegay M
AIDS; 2000 May; 14(7):791-9. PubMed ID: 10839586
[TBL] [Abstract][Full Text] [Related]
14. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
[TBL] [Abstract][Full Text] [Related]
15. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy.
Hunt PW; Deeks SG; Rodriguez B; Valdez H; Shade SB; Abrams DI; Kitahata MM; Krone M; Neilands TB; Brand RJ; Lederman MM; Martin JN
AIDS; 2003 Sep; 17(13):1907-15. PubMed ID: 12960823
[TBL] [Abstract][Full Text] [Related]
16. The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy.
Staszewski S; Babacan E; Stephan C; Haberl A; Carlebach A; Gute P; Klauke S; Hermschulte Y; Stuermer M; Dauer B;
J Antimicrob Chemother; 2006 Nov; 58(5):1024-30. PubMed ID: 16956902
[TBL] [Abstract][Full Text] [Related]
17. Treatment history and baseline viral load, but not viral tropism or CCR-5 genotype, influence prolonged antiviral efficacy of highly active antiretroviral treatment.
Bratt G; Karlsson A; Leandersson AC; Albert J; Wahren B; Sandström E
AIDS; 1998 Nov; 12(16):2193-202. PubMed ID: 9833861
[TBL] [Abstract][Full Text] [Related]
18. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
Hammer SM; Vaida F; Bennett KK; Holohan MK; Sheiner L; Eron JJ; Wheat LJ; Mitsuyasu RT; Gulick RM; Valentine FT; Aberg JA; Rogers MD; Karol CN; Saah AJ; Lewis RH; Bessen LJ; Brosgart C; DeGruttola V; Mellors JW;
JAMA; 2002 Jul; 288(2):169-80. PubMed ID: 12095381
[TBL] [Abstract][Full Text] [Related]
19. Two decades of HIV infection in a cohort of haemophilic individuals: clinical outcomes and response to highly active antiretroviral therapy.
Sabin CA; Yee TT; Devereux H; Griffioen A; Loveday C; Phillips AN; Lee CA
AIDS; 2000 May; 14(8):1001-7. PubMed ID: 10853982
[TBL] [Abstract][Full Text] [Related]
20. Pattern and predictors of immunologic recovery in human immunodeficiency virus-infected children receiving non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy.
Puthanakit T; Kerr S; Ananworanich J; Bunupuradah T; Boonrak P; Sirisanthana V
Pediatr Infect Dis J; 2009 Jun; 28(6):488-92. PubMed ID: 19504731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
